Major Survival Gain With Immunotherapy in Lymphomatoid Granulomatosis Median overall survival reached 20 years with interferon alfa-2b in low-grade disease Apr 05, 2023
FDA Greenlights First Drug for Rare Immunodeficiency Disease Activated PI3K-delta syndrome may have a new standard of care Mar 27, 2023
Make the Diagnosis: This Bump on His Nose is a Tricky Diagnosis A 52-year-old man visited his doctor for a new growth on his nose. Can you diagnosis the patient? Mar 27, 2023
Sam Neill's Rare Lymphoma The actor noticed swollen glands while on tour for "Jurassic World Dominion" Mar 23, 2023
Sickle Cell Disease Patients Miss Out on Decades of Life What effects might emerging therapies have on real-world survival? Mar 17, 2023
FDA Panel Endorses New First-Line Lymphoma Regimen POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimen Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
Full-Dose Anticoagulation Again Favored for COVID Admissions Despite failures, FREEDOM trial supports mortality advantage in general ward use Mar 07, 2023
Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advances News, features, and commentary about cancer-related issues Mar 03, 2023
Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoe News, features, and commentary about cancer-related issues Feb 24, 2023
Gene Tx Shows Sustained Bleeding Control in Severe Hemophilia A at 2 Years Model predicts valoctocogene roxaparvovec could maintain mild hemophilia levels for 5 years Feb 23, 2023
Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia A Weekly dosing with efanesoctocog alfa reduced annualized bleeding rate by 77% Jan 25, 2023
Inflammatory VEXAS Syndrome May Not Be So Uncommon Is new disease being missed by physicians? Jan 24, 2023
Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complication Observational study provides suggestive evidence Jan 17, 2023
Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
Early Win for Gene Therapy in Rare Form of SCID 10 infants were able to make their own T cells; safety good so far Dec 21, 2022
Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria Iptacopan improved hemoglobin without transfusion versus current standard of care Dec 14, 2022
Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod Glycoprotein receptor inhibitor produces four times as many responses as placebo Dec 12, 2022
Black Patients Less Likely to Get Advanced Treatments for PE Also less likely for patients on Medicare and Medicaid Dec 12, 2022
AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients Dec 11, 2022
Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone Dec 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
FDA OKs First Gene Therapy for Hemophilia B Hemgenix reduced rate of annual bleeds, eliminated need for factor IX prophylaxis therapy Nov 22, 2022
Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma No increased risk to patients with other hematologic malignancies, meta-analysis shows Nov 02, 2022
Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standard Europe and other countries have already followed suit Nov 01, 2022
FDA Broadens Options for Relapsed/Refractory Multiple Myeloma With Teclistamab Bispecific antibody achieved durable responses in a majority of heavily pretreated patients Oct 25, 2022
Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
